Hematological Profiles of Patients Suffering from Severe and Non-Severe COVID-19 Infection

  • Adam Umair Ashraf Butt
  • Abdur Rehman Malik
  • Muhammad Sarfraz Khan
  • Saqlain Ghazanfar
  • Areeb Khalid
  • Hafiz Tanveer Tariq
  • Safi Ullah
  • Muhammad Mujeeb Khan
Keywords: Blood platelets, COVID-19, neutrophils, leukocyte count, partial thromboplastin time, prothrombin time, thrombocytopenia.


Background: The current COVID-19 pandemic has had devastating effects on the lives of people all over the globe. Thus, it is important to identify differences between the severity levels of the disease to understand pathophysiology better and therefore, come up with more efficient ways to diagnose and combat it. The objective of this study is to analyze the hematological profile of non-severe & severe patients at the time of presentation in tertiary health care set up and identify any differences between them.
Materials and Methods: A comparative retrospective study was carried out among patients visiting the Infectious Diseases Department at Holy Family Hospital, Rawalpindi through systematic random sampling. The self-structured questionnaire consisted of 1) Sociodemographic details and 2) Hematological profile (samples taken at the time of admission). The hematological profile consisted of hemoglobin (Hb), white blood cell count (WBCs), platelets (PLT), neutrophils, prothrombin time (PT), and activated partial thromboplastin time (APTT). Continuous variables were compared by the Mann–Whitney U test and enumeration variables were compared by Pearson χ2 or Fisher exact test, where appropriate.
Results: Out of 106 patients, fifty-eight (54.7%) were non-severe while 48(45.3%) were severe at the time of presentation. In our study, there was a lower level of platelets and consequently, more thrombocytopenia in severe patients comparatively. A significantly longer PT time was also observed in severe patients. Our results showed a marked difference in the levels of hemoglobin between the two groups, along with an increased incidence of neutrophilia in patients with severe outcomes.
Conclusion: Thrombocytopenia, neutrophilia, and falling hemoglobin levels are the hematological factors that differ significantly between severe and non-severe forms of the disease.


1. Zhu N, Zhang D, Wang W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019 [published January 24, 2020]. N Engl J Med.
2. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. [cited 2020 Jul 30]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
3. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. The Lancet. Gastroenterology & Hepatology. 2020;5(6):529.
4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42.
6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
7. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine. 2020;8(4):420-2.
8. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020;63(3):364-74.
9. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunologic research. 2014;59(1-3):118-28.
10. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. Journal of Infection. 2020;80(4);401-406
11. Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, et al. Hematological findings and complications of COVID‐19. American journal of hematology. 2020;95(7):834-847.
12. Liu X, Zhang R, He G. Hematological findings in coronavirus disease 2019: indications of progression of disease. Ann Hematol. 2020;99(7):1421-1428.
13. Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, et al. Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China. American Journal of Roentgenology. 2020:1-6.
14. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.
15. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20..
16. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
How to Cite
Butt AU, Malik AR, Khan M, Ghazanfar S, Khalid A, Tariq H, Ullah S, Khan M. Hematological Profiles of Patients Suffering from Severe and Non-Severe COVID-19 Infection. JRMC [Internet]. 12Dec.2020 [cited 8May2021];24(1):3-. Available from: https://journalrmc.com/index.php/JRMC/article/view/1532